Medical Oncologist
HER2-positive cancer
When Trastuzumab Stops Working: — Resistance and What Comes Next
Trastuzumab eventually stops controlling the cancer in a proportion of patients. When that happens, there are approved next-line treatments, and your oncologist will have a plan.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance is expected in some patients — Trastuzumab does not work indefinitely for everyone. This is a known part of HER2-positive cancer treatment, not a failure of your care.
- Approved next-line options exist — Several treatments have demonstrated benefit after trastuzumab progression, backed by NCCN, ASCO, and ESMO guidance.
- The choice depends on your history — Which treatment comes next depends on what you have already had, where the cancer has spread, and your general health.
- Clinical trials are worth asking about — New HER2-targeted approaches are actively being studied. Ask your oncologist whether a trial is open for your situation.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
When trastuzumab stops controlling HER2-positive cancer, several approved treatments are available as next steps. NCCN and ASCO guidance describes options including trastuzumab deruxtecan, T-DM1, and tucatinib-based combinations. Which one your oncologist recommends depends on what you have already had, where the cancer has spread, and your overall fitness.
Why does trastuzumab stop working?
Trastuzumab works by binding to HER2 receptors on cancer cells and blocking the signals that tell them to grow. Resistance develops when the cancer finds ways to bypass that block.
Some cancers show primary resistance, meaning they do not respond from the start. Others develop acquired resistance after an initial period of disease control — the cancer adapts over months or years.
Common mechanisms include changes in the HER2 receptor itself, activation of alternative growth pathways such as PI3K, and loss of the protein that trastuzumab needs to attach to. The cancer is not becoming stronger overall; it is finding a different route to grow.
Resistance to trastuzumab does not mean resistance to every HER2-targeted agent. Many next-line treatments are designed specifically to work despite these resistance mechanisms.
What to do when trastuzumab stops working
- Do not stop treatment without a plan in placeStopping abruptly can allow the cancer to progress faster. Your oncologist will move you directly to the next appropriate treatment.
- Ask which next-line option is being recommended and whyThe choice between available options is not arbitrary. Understanding the reason helps you ask the right follow-up questions.
- Ask whether re-testing your tumour tissue would change the planSome cancers change their molecular profile over time. A repeat biopsy is not always necessary but is worth discussing.
- Ask about clinical trialsTrials of newer HER2-targeted agents are actively recruiting in India. Eligibility depends on your specific situation and treatment history.
- Seek a second opinion if you are uncertainIt is entirely reasonable to want another oncologist to review the plan before starting a new treatment.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
The main options after trastuzumab: what each one is
- Trastuzumab deruxtecan (T-DXd)
- An antibody-drug conjugate — trastuzumab carries a chemotherapy payload directly into HER2-expressing cells. ASCO and ESMO guidance describes it as a preferred next-line option in HER2-positive breast cancer after prior trastuzumab and pertuzumab.
- Trastuzumab emtansine (T-DM1)
- Another antibody-drug conjugate carrying a different chemotherapy payload. It is included in NCCN guidance as an option for patients who have not previously received it.
- Tucatinib with trastuzumab and capecitabine
- A three-drug combination using tucatinib, a tyrosine kinase inhibitor that targets HER2 inside the cell, alongside continued trastuzumab and oral chemotherapy. ASCO guidance notes particular evidence in patients with brain metastases.
- Lapatinib-based regimens
- An established tyrosine kinase inhibitor used in combination with capecitabine or other agents. It remains an option in later lines where newer agents are not available.
- Pertuzumab
- A second HER2-targeted antibody that binds at a different site on the receptor from trastuzumab. It may be an option in combination if it was not part of your initial treatment.
- Clinical trials
- Newer agents — including bispecific antibodies and next-generation conjugates — are being studied in HER2-positive disease. Your oncologist can tell you whether a trial is open and whether you are eligible.
How your oncologist decides what comes next
The choice between options depends on which treatments you have already had and how well you tolerated them. No two treatment histories are identical, which is why the answer varies between patients.
Where the cancer has spread also matters. Tucatinib-based combinations, for example, have specific evidence in patients whose cancer has reached the brain — evidence that not all regimens share.
Your general health and how well you are able to manage an oral medicine at home both influence which treatment is practical. These are not obstacles to finding you something — they are the information your oncologist uses to find what will work best for your situation.
If you feel unclear about why one option was chosen over another, that is a reasonable question to ask directly. A clear explanation is something you are entitled to expect.
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does trastuzumab resistance mean my cancer is untreatable?
No. Resistance to trastuzumab means that specific drug is no longer controlling the cancer — it does not mean HER2-targeted treatment has failed altogether. Several other approved drugs work through different mechanisms on the same HER2 pathway, and the cancer remaining HER2-positive is what makes those options possible. Resistance to one agent is an expected part of treating metastatic HER2-positive disease and is something your oncologist plans for in advance.
Will I stay on HER2-targeted treatment after trastuzumab stops working?
In most cases, yes. Your cancer's HER2-positive status is still the main vulnerability, and most next-line options continue to target HER2 through a different mechanism. Trastuzumab deruxtecan and T-DM1, for example, combine HER2-targeting with a chemotherapy payload in a single drug. Whether you also receive separate chemotherapy depends on which option is recommended and your overall treatment history.
What is trastuzumab deruxtecan and how is it different from trastuzumab?
Trastuzumab deruxtecan uses the same antibody as trastuzumab to locate HER2-positive cells, but it carries a chemotherapy drug attached to it. When the molecule enters a cancer cell, the chemotherapy payload is released inside. This concentrates the effect in HER2-expressing cells rather than throughout the body. ASCO and ESMO guidance describes it as a preferred next-line option in HER2-positive breast cancer after prior trastuzumab and pertuzumab, based on evidence from clinical trials.
Can I become resistant to the next drug as well?
In a proportion of patients, yes, over time. Acquired resistance is a feature of metastatic cancer rather than a specific property of any one drug. That is one reason why clinical trials of newer agents continue and why your oncologist will consider several lines of treatment in sequence rather than planning only one step ahead. If resistance develops to a second drug, further options may still exist depending on your treatment history and what has been approved since you started.
Do I need a repeat biopsy when trastuzumab stops working?
Not always, but it is worth discussing. In a proportion of patients, the molecular profile of the cancer changes between initial diagnosis and later progression. A repeat biopsy can confirm the cancer is still HER2-positive and may identify additional changes — such as a mutation — that open new treatment options. Whether the result would actually change your recommended treatment is the practical question to put to your oncologist before deciding whether to proceed.
Are these next-line treatments available at CION?
CION treats HER2-positive cancer across 35 or more centres in Telangana and Andhra Pradesh, and your oncologist will advise which next-line options apply to your situation. CION does not provide CAR-T or cell therapy. For any treatment that requires specialist coordination or a clinical trial site, your treating team will discuss the pathway with you and what is accessible in your region.